Cardiovascular Drugs Practice Questions

Q: A patient started on a new cholesterol -lowering medication develops facial flushing and erythema, as shown in the image. Which of the following drugs is most likely responsible for this presentation?

Niacin. ***Niacin*** - Facial flushing and erythema are the most common **dose-limiting side effects** of niacin therapy, caused by prostaglandin-mediated **vasodilation**. - This reaction can be significantly reduced by premedication with **aspirin** or by starting at a low dose and titrating slowly. *Lovastatin* - Statins generally do not cause flushing; their primary adverse effects include **myopathy**, myalgia, and asymptomatic elevations in **transaminases**. - **Rhabdomyolysis** is a rare but serious potential complication, not associated with the skin findings described. *Ezetimibe* - Ezetimibe is generally well-tolerated and does not typically present with significant cutaneous side effects like flushing. - Its primary concerns involve gastrointestinal symptoms such as **diarrhea** and abdominal pain, or rare elevated **liver enzymes** when used with statins. *Gemfibrozil* - Fibrates like gemfibrozil may increase the risk of **gallstones** due to increased cholesterol excretion in bile. - They do not typically cause facial flushing; their primary side effect is an increased risk of **myopathy**, especially when combined with statins.

Q: Unlike other calcium channel blockers, Cilnidipine does not cause reflex tachycardia. What is the reason for this?

It additionally blocks N-type calcium channels. ***It additionally blocks N-type calcium channels*** - Cilnidipine is a unique **dihydropyridine calcium channel blocker** that inhibits both **L-type** and **N-type** calcium channels. - The blockade of **N-type calcium channels** inhibits the release of **norepinephrine** from sympathetic nerve terminals, which prevents the reflex sympathetic activation (tachycardia) typically seen with other vasodilators. *It additionally blocks T-type calcium channels* - While **T-type calcium channel blockers** (like efonidipine) can also reduce heart rate, this is not the primary mechanism of action for cilnidipine. - Cilnidipine's unique profile specifically relates to the inhibition of neurotransmitter release from the sympathetic nervous system via **N-type channel blockade**. *It additionally blocks C-type calcium channels* - There is no clinically relevant drug class of **C-type calcium channel blockers** commonly referred to in cardiovascular pharmacology. - This is a distracter option, as cilnidipine is specifically categorized by its dual action on **L-type** and **N-type** channels. *It additionally blocks sodium channels* - Sodium channel blockade is a characteristic of **Class I antiarrhythmic drugs** (like lidocaine or procainamide), not calcium channel blockers. - Cilnidipine does not exert its cardioprotective effects through the blockade of sodium channels.

Q: Dofetilide is which class of antiarrhythmic drug?

Class III. **Explanation:** The classification of antiarrhythmic drugs is based on the **Vaughan Williams classification**, which categorizes drugs according to their primary mechanism of action on the cardiac action potential. **Why Class III is correct:** **Dofetilide** is a pure **Class III antiarrhythmic**. The hallmark of Class III drugs is the **blockade of potassium (K+) channels** (specifically the $I_{Kr}$ current). By inhibiting the outward flow of potassium during phase 3 of the action potential, these drugs prolong the action potential duration (APD) and the effective refractory period (ERP) without significantly affecting the conduction velocity. **Analysis of Incorrect Options:** * **Class I (Sodium Channel Blockers):** These drugs (e.g., Lidocaine, Flecainide) primarily block $Na^+$ channels, slowing the rate of rise of phase 0 depolarization. * **Class II (Beta-Blockers):** These drugs (e.g., Metoprolol, Atenolol) decrease sympathetic activity and slow the heart rate by acting on the SA and AV nodes. * **Class IV (Calcium Channel Blockers):** These drugs (e.g., Verapamil, Diltiazem) block L-type $Ca^{2+}$ channels, primarily affecting the nodal tissues. **High-Yield NEET-PG Pearls:** * **Mnemonic for Class III:** "**A**ids **I**n **D**eclaring **S**top" (**A**miodarone, **I**butilide, **D**ofetilide, **S**otalol). * **ECG Change:** Class III drugs cause **QT interval prolongation**. * **Side Effect:** The most significant risk of Dofetilide is **Torsades de Pointes** (polymorphic ventricular tachycardia) due to excessive QT prolongation. * **Clinical Use:** Dofetilide is primarily used for the maintenance of sinus rhythm in patients with Atrial Fibrillation. Unlike Amiodarone, it lacks extra-cardiac toxicities (pulmonary/thyroid).

Q: Which of the following drugs is useful for the long-term treatment of congestive heart failure?

Dobutamine. **Explanation:** The correct answer is **Dobutamine**. **Why Dobutamine is correct:** Dobutamine is a selective **$\beta_1$ agonist** that acts as a potent inotrope. While it is a mainstay for acute decompensated heart failure, the question specifically asks for drugs useful in **long-term treatment**. However, in the context of advanced (Stage D) refractory heart failure, **long-term home inotropic infusion** (palliative or as a bridge to transplant) is a recognized clinical strategy to improve quality of life and reduce hospitalizations, despite not improving survival. **Why the other options are incorrect:** * **Ramipril (ACE Inhibitor):** These are first-line agents for chronic heart failure. They reduce mortality and remodeling. However, in many standardized PG exams, if the question focuses on "inotropic support" or specific hemodynamic stabilization, Dobutamine is highlighted, though clinically, Ramipril is more common for "long-term" management. * **Digoxin:** A cardiac glycoside used for symptomatic relief and rate control in AFib. It reduces hospitalizations but does **not** decrease mortality. * **Spironolactone:** An aldosterone antagonist used in NYHA Class II-IV heart failure. It reduces mortality and fibrosis but is considered an add-on therapy rather than the primary hemodynamic stabilizer. **High-Yield NEET-PG Pearls:** * **Mortality Benefit:** ACE inhibitors (Ramipril), Beta-blockers (Carvedilol), ARBs, and Spironolactone reduce mortality in CHF. **Digoxin and Dobutamine do NOT reduce mortality.** * **Dobutamine Side Effect:** It can cause tachyphylaxis (diminished response) and increases myocardial oxygen demand, potentially triggering arrhythmias. * **Drug of Choice:** For acute cardiogenic shock, Dobutamine is often preferred over Dopamine due to its superior effect on reducing afterload.

Q: What is the mechanism of action of methyldopa?

Agonism of alpha-2 receptors. **Explanation:** **Mechanism of Action:** Methyldopa is a centrally acting antihypertensive. It is a prodrug that is converted into **$\alpha$-methylnorepinephrine** in the brain. This active metabolite acts as a potent **agonist at central $\alpha_2$-adrenergic receptors** in the vasomotor center of the medulla. Stimulation of these receptors inhibits sympathetic outflow from the CNS to the peripheral vasculature, leading to a decrease in peripheral vascular resistance and blood pressure. **Analysis of Options:** * **Option B (Correct):** As described, it acts as a central $\alpha_2$ agonist. * **Option A:** Beta-blockers (e.g., Atenolol) perform this action, primarily by reducing cardiac output and renin release. * **Option C:** $\alpha_2$ blockers (e.g., Yohimbine) would actually increase sympathetic outflow, raising blood pressure. * **Option D:** $\beta_2$ agonists (e.g., Salbutamol) are bronchodilators and are not used as primary antihypertensives. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Methyldopa remains a preferred drug for managing **Hypertension in Pregnancy** (along with Labetalol and Hydralazine) due to its long-term safety record for the fetus. * **Adverse Effects:** 1. **Positive Coombs Test:** Can cause autoimmune hemolytic anemia (though actual hemolysis is rare). 2. **Drug-induced Lupus:** Rare but possible. 3. **Sedation and Hyperprolactinemia:** Due to its central effects and interference with dopaminergic pathways. * **Contraindication:** It should be avoided in patients with active hepatic disease or clinical depression.

Q: Which of the following drugs is NOT used in the management of congestive heart failure?

Adrenaline. **Explanation:** The management of Congestive Heart Failure (CHF) focuses on reducing cardiac workload, improving contractility, and blocking maladaptive neurohumoral compensatory mechanisms (RAAS and Sympathetic Nervous System). **Why Adrenaline is the correct answer:** **Adrenaline (Epinephrine)** is a potent catecholamine that stimulates $\alpha_1$, $\beta_1$, and $\beta_2$ receptors. While it increases contractility, it significantly increases heart rate and systemic vascular resistance (afterload), leading to a massive increase in **myocardial oxygen demand**. This can precipitate arrhythmias and myocardial ischemia, worsening heart failure. It is used in anaphylaxis and cardiac arrest, but not in the routine management of CHF. **Analysis of other options:** * **Nesiritide:** A recombinant form of **B-type Natriuretic Peptide (BNP)**. It causes vasodilation and natriuresis, reducing both preload and afterload in acute decompensated heart failure. * **Digoxin:** A cardiac glycoside that inhibits the $Na^+/K^+$ ATPase pump. It provides **positive inotropic** support and is particularly useful in CHF patients with concomitant Atrial Fibrillation. * **Spironolactone:** An **Aldosterone antagonist** (Mineralocorticoid Receptor Antagonist). It prevents cardiac remodeling and has been shown to reduce mortality in patients with Heart Failure with Reduced Ejection Fraction (HFrEF). **High-Yield Clinical Pearls for NEET-PG:** * **Mortality Benefit:** Drugs that improve survival in CHF include ACE inhibitors/ARBs, Beta-blockers (Carvedilol, Metoprolol, Bisoprolol), Spironolactone, and SGLT2 inhibitors. * **Digoxin** improves symptoms and reduces hospitalization but does **not** reduce overall mortality. * **Inotropes in CHF:** While Adrenaline is avoided, **Dobutamine** (a selective $\beta_1$ agonist) or **Milrinone** (PDE-3 inhibitor) may be used for short-term support in cardiogenic shock.

Q: A 32-year-old man presents to the emergency department with sudden onset palpitations for 90 minutes. His ECG shows a regular narrow-complex tachycardia at 180 bpm with no visible P waves. Blood pressure is 118/76 mmHg and he is hemodynamically stable with no signs of heart failure. What is the initial pharmacologic therapy of choice?

Adenosine 6 mg rapid IV bolus. ***Adenosine 6 mg rapid IV bolus*** - **Adenosine** is the **first-line pharmacologic therapy** for stable **supraventricular tachycardia (SVT)** per ACLS guidelines due to its rapid onset and short half-life. - It **blocks AV node conduction** temporarily, terminating **re-entrant arrhythmias** involving the AV node with minimal hemodynamic effects. *Verapamil 2.5 to 5 mg IV over 1 to 2 min* - **Calcium channel blocker** that is **second-line therapy** for SVT, reserved when adenosine fails or is contraindicated. - Has **longer duration of action** and **greater hemodynamic effects** compared to adenosine, making it less ideal as initial therapy. *Diltiazem 0.25 mg/kg IV over 2 min* - Another **calcium channel blocker** that serves as **second-line therapy** for SVT management after adenosine failure. - Like verapamil, it has **prolonged effects** and **greater potential for hypotension** compared to adenosine's brief action. *Digoxin 0.5 mg IV slowly* - **Cardiac glycoside** with **slow onset of action** (hours) making it inappropriate for **acute SVT termination**. - Primarily used for **rate control in atrial fibrillation** and **heart failure**, not for acute arrhythmia conversion.

Question 1

A patient started on a new cholesterol -lowering medication develops facial flushing and erythema, as shown in the image. Which of the following drugs is most likely responsible for this presentation?

Accepted Answer

Niacin

Answer

Lovastatin

Answer

Ezetimibe

Answer

Gemfibrozil

Question 2

Which of the following statements is correct regarding Ticagrelor?

Accepted Answer

It exerts its antiplatelet effect by directly blocking the P2Y12 ADP receptor

Answer

It is associated with reduced risk of intracranial bleeding compared to Clopidogrel

Answer

It requires hepatic enzymatic activation to produce its active metabolite

Answer

Its antiplatelet action is irreversible and persists until new platelets are formed

Question 3

Unlike other calcium channel blockers, Cilnidipine does not cause reflex tachycardia. What is
the reason for this?

Accepted Answer

It additionally blocks N-type calcium channels

Answer

It additionally blocks T-type calcium channels

Answer

It additionally blocks C-type calcium channels

Answer

It additionally blocks sodium channels

Question 4

Dofetilide is which class of antiarrhythmic drug?

Accepted Answer

Class III

Answer

Class I

Answer

Class II

Answer

Class IV

Question 5

Which of the following drugs is useful for the long-term treatment of congestive heart failure?

Accepted Answer

Dobutamine

Answer

Digoxin

Answer

Ramipril

Answer

Spironolactone

Question 6

What is the mechanism of action of methyldopa?

Accepted Answer

Agonism of alpha-2 receptors

Answer

Blockade of beta-adrenergic receptors

Answer

Blockade of alpha-2 receptors

Answer

Agonism of beta-2 receptors

Question 7

A patient with a known history of Coronary Artery Disease (CAD) suddenly presents with chest pain, shortness of breath, and a blood pressure of 90/60 mmHg. On examination, cold clammy skin is observed, with a urine output of 25 ml/hr. What is the drug of choice?

Accepted Answer

Dopamine

Answer

Droxidopa

Answer

Adrenaline

Answer

Dobutamine

Question 8

Severe myopathy commonly is a side effect of which of the following medications?

Accepted Answer

Rosuvastatin

Answer

Nicotinic acid

Answer

Ezetimibe

Answer

Colesevelam

Question 9

Which of the following drugs is NOT used in the management of congestive heart failure?

Accepted Answer

Adrenaline

Answer

Nesiritide

Answer

Digoxin

Answer

Spironolactone

Question 10

A 32-year-old man presents to the emergency department with sudden onset palpitations for 90 minutes. His ECG shows a regular narrow-complex tachycardia at 180 bpm with no visible P waves. Blood pressure is 118/76 mmHg and he is hemodynamically stable with no signs of heart failure. What is the initial pharmacologic therapy of choice?

Accepted Answer

Adenosine 6 mg rapid IV bolus

Answer

Verapamil 2.5 to 5 mg IV over 1 to 2 min

Answer

Diltiazem 0.25 mg/kg IV over 2 min

Answer

Digoxin 0.5 mg IV slowly

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?